Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/7216
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPriskila, Miranda-
dc.contributor.authorFebrina, Ellin-
dc.date.accessioned2024-11-01T03:55:57Z-
dc.date.available2024-11-01T03:55:57Z-
dc.date.issued2023-08-
dc.identifier.citationOriginal Articleen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/7216-
dc.description.abstractSingle chain fragment variable (scFv) is a recombinant antibody consisting of an antigen-binding (Fab) antibody fragment with a very small size of about 26 -27 kDa. In general, scFv is stable, encoded by a single gene so that it will facilitate genetic modification. Compared with complete antibodies, scFv which has similar antigen binding activity has other advantages such as small size, better penetration into blood vessels and tissues, and lower immunogenicity. Therefore, scFv has a very good potential to be used as a guide compound for diagnosis and therapy of disease. The results of various studies show that scFv antiHER2 (Human Epidermal Growth Factor Receptor 2) can be used as a guide in the diagnosis of HER2+ breast cancer using either Magnetic Resonance Imaging (MRI) or positron-emission tomography (PET). In HER2 receptor-targeted breast cancer therapy, anti-HER2 scFv also has the potential to be used as a guide for immunotoxins, antibody-drug conjugate (ADC), prodrugs, and pretargeted radioimmunotherapy (PRIT)en_US
dc.language.isootheren_US
dc.publisherJurnal Sains Farmasi & Klinisen_US
dc.subjectscFven_US
dc.subjectHER2+ breast canceren_US
dc.subjectargeted therapyen_US
dc.subjecttargeted diagnosticsen_US
dc.titleReview: Single Chain Fragment Variable sebagai Pemandu Diagnosis dan Terapi Bertarget Human Epidermal Growth Factor Receptor 2 Kanker Payudaraen_US
dc.typeArticleen_US
Appears in Collections:VOL 10 NO 2 2023

Files in This Item:
File Description SizeFormat 
155-161.pdf652.21 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.